On December 12, 2023, Craig S. Gilgallon, General Counsel, informed Cingulate Inc. that he was resigning as an officer of the company and was terminating employment with Cingulate Therapeutics LLC effective on December 15, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7172 USD | +2.46% | -13.07% | -90.62% |
05-21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
05-08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-90.62% | 4.36M | |
+52.36% | 56.69B | |
-3.86% | 41B | |
+38.14% | 38.11B | |
-12.01% | 26.89B | |
+14.13% | 25.59B | |
-21.62% | 18.59B | |
+0.21% | 12.39B | |
+25.96% | 11.99B | |
+23.02% | 11.88B |
- Stock Market
- Equities
- CING Stock
- News Cingulate Inc.
- Cingulate Inc. and Cingulate Therapeutics LLC Announce Resignation of Officer